Breakthrough Medication Introduction by Pharmaceutical Giant May Unlock Nearly $3 Billion in Annual Sales by Next Year

Table of Contents Eli Lilly has achieved a significant milestone in the obesity treatment market. The FDA has given the green light to orforglipron — commercially known as Foundayo — representing the pharmaceutical giant’s inaugural daily oral pill for weight management and posing a substantial competitive threat to Novo Nordisk’s market position. JUST IN: FDA approves Eli Lilly's $LLY GLP-1 weight loss pill, Foundayo. Ships from LillyDirect on Monday. Available at pharmacies shortly after. Pricing: $25/month with insurance, $149-$349 out of pocket depending on dose. The pill shows ~12.4% average weight loss vs ~16.6%… pic.twitter.com/4V8iXK9BIV — WOLF (@WOLF_Financial) April 1, 2026 During clinical testing, participants taking Foundayo experienced weight reduction ranging from 12% to 15% of their baseline body weight. The medication works by activating the GLP-1 hormone pathway, identical to the mechanism utilized by Novo’s injectable products Ozempic and Wegovy. The pharmaceutical company plans to make Foundayo available starting April 6 exclusively through its LillyDirect distribution channel. Patients paying out-of-pocket can obtain the entry-level dosage for $149 monthly — strategically matching Ozempic’s price point. Eli Lilly and Company, LLY Chief Executive David Ricks announced that regulatory filings for Foundayo have been submitted across more than 40 nations, indicating an aggressive global expansion strategy is underway. Financial analysts have responded with optimism. Projections for 2026 revenues span from $1.5 billion to $2.8 billion, with Citi leading the bullish forecasts at $2.8B and suggesting peak yearly revenues could surpass $40 billion. J.P. Morgan anticipates sales hitting $6 billion by 2027. Bernstein adopted a more conservative short-term outlook, noting that complimentary sampling programs, lower starting doses and pricing pressures might suppress initial revenue performance, despite potentially robust prescription growth. Industry observers will closely monitor weekly new patient enrollment figures. Foundayo also benefits from production advantages. The pill format is simpler to manufacture than injectable GLP-1 medications, potentially enabling Lilly to expand capacity more rapidly — especially in global markets where injectable products have encountered supply limitations. Lilly reports accumulating $1.5 billion in pre-launch stock, a strategic decision stemming from supply shortages that affected its injectable medications Zepbound and Mounjaro. These availability gaps created opportunities for compounding pharmacies across the United States to market alternative versions. The company has subsequently pursued legal remedies against compounders and wellness facilities distributing products purporting to contain tirzepatide. Novo Nordisk continues to compete actively. The Copenhagen-based pharmaceutical firm has countered with subscription-based pricing models and product modifications. UBS analysts estimate the combined oral portfolios from both competitors could generate approximately $5 billion in 2026, highlighting rapid expansion within the obesity treatment sector. Morningstar forecasts that oral obesity medications could capture roughly one-third of a $180 billion worldwide market by 2034. Lilly is moving forward with the acquisition of Centessa Pharmaceuticals in a transaction initially priced near $6.3 billion, broadening its pipeline into sleep-wake disorder treatments and narcolepsy therapeutics. A legal firm has initiated an investor investigation regarding the Centessa transaction process, potentially creating complications before deal completion. Among institutional investors, Westend Capital Management established a fresh stake in LLY during Q4, acquiring 16,393 shares valued at approximately $17.6 million. LLY currently represents about 4.9% of Westend’s holdings. The company reported Q4 earnings per share of $7.54, exceeding expectations of $7.48, alongside revenue of $19.29 billion versus consensus estimates of $17.85 billion. Revenue climbed 42.6% compared to the prior year. Management established FY2026 EPS guidance between $33.50 and $35.00. Among 30 analysts tracking the stock, 23 assign Buy ratings, four recommend Hold, and one rates it Sell. The average price objective stands at $1,221.26.